Año 2023 / Volumen 115 / Número 12
Carta
Tofacitinib-induced eosinophilia

742

DOI: 10.17235/reed.2023.9831/2023

Sara Archer, Daniela Ferreira, Ana Teresa Ferreira, Sofia Ponte, Cidalina Caetano, Marta Salgado, Paula Lago, Isabel Pedroto,

Resumen
Tofacitinib is an oral small molecule JAK inhibitor approved for the treatment of moderate to severe ulcerative colitis (UC). Its efficacy and safety have been demonstrated in phase III clinical trials and supported by real-life data. We report the case of an 18-year-old woman with a 1-year diagnosis of left-sided UC, with multiple admissions due to disease exacerbation or infections, refractory to infliximab (with azathioprine) and currently under treatment with vedolizumab and tacrolimus. She was admitted due to a severe disease exacerbation and, because of a previous history of neuropsychiatric side effects to corticotherapy, tofacitinib was initiated. In the following 6 days, there was no clinical improvement of UC, and serial blood work-up revealed moderate grade persistent peripheral eosinophilia (3000 cells/mm3) and acute kidney injury grade 1 KDIGO. Tofacitinib temporary suspension was decided, with a rapid normalization of renal function/eosinophil levels. Tofacitinib was restarted 2 days after its suspension. However, she developed moderate eosinophilia (2000 cells/mm3) again, which was considered an adverse effect (AE) to tofacitinib, leading to its suspension with eosinophilia resolution. Given the severity of the disease, after a multidisciplinary discussion, it was decided to start high-dose corticotherapy and ustekinumab with maintenance therapy every 4 weeks, and to add tacrolimus. Clinical and biochemical remission were achieved, and the patient was discharged. Three-month follow-up after tofacitinib suspension showed no recrudescence of eosinophilia. Tofacitinib represents a significant advance in the management of UC patients. The drug has a good safety profile with few related AE. This case aims to warn about an adverse reaction to tofacitinib not reported so far, including in a multicenter real-life setting recently published by Hernández et al where eosinophilia is also not described, thus emphasizing the rarity of this AE. To our knowledge this is the first case of tofacitinib-induced eosinophilia in the context of UC. 
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1 - Sandborn, W. J., Su, C., Sands, B. E., D'Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., Friedman, G., Lawendy, N., Yu, D., Woodworth, D., Mukherjee, A., Zhang, H., Healey, P., Panés, J., & OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators (2017). Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. The New England journal of medicine, 376(18), 1723–1736. https://doi.org/10.1056/NEJMoa1606910
2 - Lasa, J. S., Olivera, P. A., Danese, S., & Peyrin-Biroulet, L. (2022). Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. The lancet. Gastroenterology & hepatology, 7(2), 161–170. https://doi.org/10.1016/S2468-1253(21)00377-0
3 - Hernández Martínez A, Navajas Hernández P, Martín Rodríguez MDM, et al. Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia. Revista Espanola de Enfermedades Digestivas. 2022 Sep;114(9):516-521. DOI: 10.17235/reed.2022.8380/2021. PMID: 35000397.
Artículos relacionados

Carta

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Carta

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Carta

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Carta

Síndrome de DRESS secundario a carbamazepina

DOI: 10.17235/reed.2022.8977/2022

Carta

Neumonitis intersticial por mesalazina en la era COVID

DOI: 10.17235/reed.2022.8635/2021

Carta

Efecto del Adacolumn® en colitis ulcerosa con COVID-19

DOI: 10.17235/reed.2020.7156/2020

Carta

Síndrome de Sweet en el brote grave de colitis ulcerosa

DOI: 10.17235/reed.2020.6995/2020

Carta al Editor

Colitis ulcerosa con afectación gástrica y duodenal

DOI: 10.17235/reed.2017.4685/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Caso Clínico

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Instrucciones para citar
Archer S, Ferreira D, Ferreira A, Ponte S, Caetano C, Salgado M, et all. Tofacitinib-induced eosinophilia . 9831/2023


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 931 veces.
Este artículo ha sido descargado 92 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 10/07/2023

Aceptado: 18/07/2023

Prepublicado: 04/08/2023

Publicado: 12/12/2023

Tiempo de prepublicación: 25 días

Tiempo de edición del artículo: 155 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas